Search

Your search keyword '"Immunotherapy -- Technology application"' showing total 250 results
Start Over Descriptor "Immunotherapy -- Technology application"
250 results on '"Immunotherapy -- Technology application"'

51. Promontory Therapeutics Receives U.S. Patent for Therapeutic Applications of PT-112 as an Immuno-Modulatory Agent

Subjects
Immunotherapy -- Technology application, Technology application, General interest, News, opinion and commentary
Abstract

NEW YORK: Promontory Therapeutics Inc. has issued the following news release: Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, today announced the United States [...]

Published
2022

52. Study Data from University of Oxford Update Knowledge of Pluripotent Stem Cells (Induced pluripotent stem cells reprogrammed from primary dendritic cells provide an abundant source of immunostimulatory dendritic cells for use in immunotherapy)

Subjects
Immunotherapy -- Technology application, Dendritic cells -- Technology application, Stem cells -- Technology application, Stem cell research -- Technology application, Technology application, Health, University of Oxford -- Technology application
Abstract

2020 NOV 23 (NewsRx) -- By a News Reporter-Staff News Editor at Stem Cell Week -- Current study results on Stem Cell Research - Pluripotent Stem Cells have been published. [...]

Published
2020

53. DBV Technologies says seven abstracts accepted at EAACI meeting

Subjects
Food hypersensitivity -- Technology application, Immunotherapy -- Technology application, Technology, Conferences and conventions, Allergy, Technology application, Business, News, opinion and commentary
Abstract

DBV Technologies announced last night that seven abstracts, including four late breakers, highlighting new data from the company's pre-clinical and clinical food allergy programs were accepted at the European Academy [...]

Published
2020

54. OncoSec's TAVO and its electroporation gene delivery system receives European & Canadian patents

Subjects
Cancer treatment -- Technology application, Genes -- Technology application, Patents -- Technology application, Immunotherapy -- Technology application, Interleukins, Cancer, Patent/copyright issue, Technology application, Pharmaceuticals and cosmetics industries
Abstract

OncoSec Medical Incorporated, a company developing late-stage intratumoral cancer immunotherapies, announced Notices of Allowance for three new patent applications covering its interleukin-12 (IL-12) based immunotherapy platform, including its lead product [...]

Published
2020

55. Valo Therapeutics to use PeptiCRAd technology to develop novel coronavirus vaccine

Subjects
Vaccines -- Technology application, Coronavirus infections -- Technology application, Coronaviruses -- Technology application, B cells -- Technology application, Immunotherapy -- Technology application, Proteins -- Technology application, T cells -- Technology application, Adenoviruses -- Technology application, Clothing, Viral proteins, Technology, Peptides, Immune response, Novels, Technology application, Pharmaceuticals and cosmetics industries
Abstract

Valo Therapeutics Limited (Valo Tx), an immuno-oncology company, announced it is working to develop a potential novel COVID-19 vaccine with applications across future pandemics. Valo Tx will use its PeptiCRAd [...]

Published
2020

56. Verismo Therapeutics Announces Submission of IND Application to the FDA for SynKIR-110, a KIR-CAR T-cell Immunotherapy Candidate

Subjects
United States. Food and Drug Administration -- Technology application -- Planning, T cells -- Technology application, Immunotherapy -- Technology application, Clinical trials -- Technology application, Drug approval -- Technology application, Ovarian cancer -- Technology application, Company business planning, Technology application, General interest, News, opinion and commentary
Abstract

PHILADELPHIA: Verismo Therapeutics has issued the following news release: Verismo Therapeutics, a Penn-spinout and the company behind the novel KIR-CAR platform technology for CAR T-cell therapy, today announced that it [...]

Published
2022

57. TScan Therapeutics Announces Publication in Cell Highlighting the Discovery of Tumor Antigens and TCRs for the Treatment of Solid Tumors Using Foundational Screening Technology

Subjects
T cells -- Technology application, Immunotherapy -- Technology application, Cancer -- Care and treatment -- Technology application, Tumor antigens -- Technology application, Technology application, Banking, finance and accounting industries, Business, Harvard University. Harvard Medical School -- Technology application
Abstract

WALTHAM, Jul 11, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NasdaqGM:TCRX), EQNX::TICKER_END TScan screening technology used to identify the targets of expanded T cell clones in the tumors of patients [...]

Published
2022

58. Four New York City Cancer Centers Receive $1 Million SU2C Grant to Improve Lung Cancer Care in Underserved Minority Patients

Subjects
Patients -- Care and treatment, Minorities -- Technology application, Cancer patients -- Care and treatment, Immunotherapy -- Technology application, Lung cancer, Non-small cell -- Care and treatment, Medical care -- Quality management, Technology application, Business, News, opinion and commentary
Abstract

NEW YORK, June 27, 2022 /PRNewswire/ -- A team of New York City lung cancer experts, led by investigators at NYU Langone Health's https://c212.net/c/link/?t=0&l=en&o=3578123-1&h=392411007&u=https%3A%2F%2Fnyulangone.org%2Flocations%2Fperlmutter-cancer-center&a=Perlmutter+Cancer+Center, have received a three-year, $1 million [...]

Published
2022

59. Northwest Biotherapeutics Announces Presentations On DCVax-L Personalized Vaccines, Manufacturing and Scale-Up, and DCVax-L Clinical Program

Subjects
United States. Securities and Exchange Commission -- Technology application, Biotechnology industry -- Technology application, Immunotherapy -- Technology application, Cancer -- Care and treatment, Vaccines -- Technology application, Technology application, Business, News, opinion and commentary
Abstract

BETHESDA, Md., June 5, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ('NW Bio'), a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, reported that yesterday on June [...]

Published
2022

60. Iaso Therapeutics Announces First Close in $1.25M Equity Series Seed Preferred Financing

Subjects
Immunotherapy -- Technology application, Antigens -- Technology application, Vaccines -- Technology application, Technology application, Health, Michigan State University -- Officials and employees
Abstract

2023 FEB 8 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- Iaso Therapeutics, a Michigan State University startup developing novel technologies for next-generation vaccines, recently closed [...]

Published
2023

61. Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV® enfortumab vedotin-ejfv with KEYTRUDA® pembrolizumab for the First-Line Treatment of Certain Patients With Locally Advanced or Metasta

Subjects
United States. Food and Drug Administration -- Technology application, Astellas Pharma Inc. -- Technology application, Seagen Inc. -- Technology application, Merck Research Laboratories -- Technology application, Biotechnology industry -- Technology application, Immunotherapy -- Technology application, Chemotherapy -- Technology application, Cancer -- Chemotherapy, Pharmaceutical industry -- Technology application, Technology application, Health, Padcev (Medication), Keytruda (Medication)
Abstract

2023 JAN 4 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., 'Astellas'), Seagen Inc. (Nasdaq: SGEN) [...]

Published
2023

62. Chiome Bioscience Inc.: Release of Research Publication using Tribody Technology onto Cancer Immunotherapy from Chiome Bioscience in collaboration with Ceinge

Subjects
Oncology, Experimental -- Technology application, Biotechnology -- Technology application, Biotechnology industry -- Technology application, Immunotherapy -- Technology application, Cancer -- Care and treatment -- Drug therapy -- Research, Technology application, General interest, News, opinion and commentary
Abstract

Tokyo: Chiome Bioscience Inc. has issued the following news release: The publication is released on a basis of th e research using our Tribody technology . Tribody tecnhology is one [...]

Published
2022

63. Celsion Corporation to Hold Year-End 2021 Financial Results and Business Update Conference Call on Thursday, March 31, 2022

Subjects
Celsion Corp. -- Technology application, Medical test kit industry -- Technology application, Immunotherapy -- Technology application, Product development -- Technology application, Medical equipment and supplies industry -- Technology application, Vaccines -- Technology application, Ovarian cancer -- Technology application, Time to market, Technology application, Banking, finance and accounting industries, Business
Abstract

LAWRENCEVILLE, Mar 24, 2022 (GLOBE NEWSWIRE via COMTEX) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will [...]

Published
2022

64. Tiziana Life Sciences to Participate in 2022 Biotech Showcase Virtual Investor Conference

Subjects
Drugs -- Vehicles, Biotechnology -- Technology application, Biotechnology industry -- Technology application, Immunotherapy -- Technology application, Drug delivery systems -- Technology application, Technology application, Banking, finance and accounting industries, Business
Abstract

NEW YORK, Jan 06, 2022 (GLOBE NEWSWIRE via COMTEX) -- Tiziana Life Sciences (Nasdaq: TLSA) ('Tiziana'), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announced [...]

Published
2022

65. Tiziana Life Sciences to Participate in 2022 Biotech Showcase Virtual Investor Conference

Subjects
Drugs -- Vehicles, Biotechnology -- Technology application, Biotechnology industry -- Technology application, Immunotherapy -- Technology application, Drug delivery systems -- Technology application, Technology application, Business, international
Abstract

(GLOBE NEWSWIRE via COMTEX) -- NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ('Tiziana'), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug [...]

Published
2022

66. Akoya Biosciences Announces a Groundbreaking Collaboration with PathAI to Combine Spatial Biology with AI-Powered Tools to Facilitate Discovery of Novel Predictive Biomarkers

Subjects
Immunotherapy -- Technology application, Biological markers -- Technology application, Technology application, Banking, finance and accounting industries, Business
Abstract

MARLBOROUGH, Mass., Dec 13, 2021 (GLOBE NEWSWIRE via COMTEX) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company, and PathAI, a global leader in artificial intelligence (AI)-powered technology for [...]

Published
2021

67. Akoya Biosciences Partners With PathAI to Combine Spatial Biology

Subjects
Immunotherapy -- Technology application, Technology application, General interest, News, opinion and commentary
Abstract

MARLBOROUGH, Mass.: Akoya Biosciences, Inc., The Spatial Biology Company(r), and PathAI, a global leader in artificial intelligence (AI)-powered technology for pathology, today announced a collaboration to advance the discovery and [...]

Published
2021

68. Avalon GloboCare files provisional patent applications for AVA-101

Subjects
Immunotherapy -- Technology application, Toxicity, Transposons, Automobiles, Rituximab, Novels, Antigens, Technology application, Business, News, opinion and commentary
Abstract

Avalon GloboCare announced that the company and Arbele have jointly filed provisional patent applications covering method and composition of matter claims for AVA-101, a novel multi-targeted, transposon-based chimeric antigen receptor, [...]

Published
2019

69. Aivita identifies mechanism to enhance patient response rate to next generation cancer stem cell immunotherapy

Subjects
Cancer -- Care and treatment -- Technology application, Immunotherapy -- Technology application, Cancer treatment -- Technology application, Stem cells -- Technology application, Medical research -- Technology application, Biotechnology, Proteins, Technology application, Pharmaceuticals and cosmetics industries
Abstract

Aivita Biomedical, a biotech company specializing in innovative stem cell applications, has previously reported a 72% 2-year survival rate and a 54% 5-year survival rate in patients treated with its [...]

Published
2019

70. Verismo Therapeutics Announces Submission of IND Application to the FDA for SynKIR-110TM, a KIR-CAR T-cell Immunotherapy Candidate

Subjects
United States. Food and Drug Administration -- Technology application -- Planning, Medical research -- Technology application, Medicine, Experimental -- Technology application, T cells -- Technology application, Immunotherapy -- Technology application, Clinical trials -- Technology application, Drug approval -- Technology application, Ovarian cancer -- Technology application, Company business planning, Technology application, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2022 AUG 29 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- Verismo Therapeutics, a Penn-spinout and the company behind the novel KIR-CAR platform technology for [...]

Published
2022

71. Automated protein-protein structure prediction of the T cell receptor-peptide major histocompatibility complex

Subjects
T cells -- Technology application, Protein structure prediction -- Technology application, Major histocompatibility complex -- Technology application, Immunotherapy -- Technology application, Peptides -- Technology application, Technology application, Health
Abstract

2022 JUN 15 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- According to news reporting based on a preprint abstract, our journalists obtained the following quote [...]

Published
2022

72. Bioengineering multifunctional extracellular vesicles for targeted delivery of biologics to T cells

Subjects
T cells -- Technology application, Immunotherapy -- Technology application, Genetic engineering -- Technology application, Genetically modified organisms -- Technology application, Technology application, Health
Abstract

2022 JUN 1 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- According to news reporting based on a preprint abstract, our journalists obtained the following quote [...]

Published
2022

73. MEDIA ALERT: Codex DNA Customer to Highlight Advantages of Automated BioXp(TM) System in Precision Cancer Immunotherapy Applications at 13th Annual PEGS Europe Protein and Antibody Engineering Summit

Subjects
DNA -- Technology application, Viral antibodies -- Technology application, Immunotherapy -- Technology application, Cancer -- Care and treatment -- Drug therapy, Proteins -- Technology application, Antibodies -- Technology application, Technology application, Banking, finance and accounting industries, Business
Abstract

San Diego, CA, Nov 01, 2021 (GLOBE NEWSWIRE via COMTEX) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that one of its [...]

Published
2021

74. Evaxion Biotech Lauded by Frost & Sullivan for Helping Develop Highly Targeted Therapies with Its AI Immunology Platforms

Subjects
Biotechnology -- Technology application, Drug discovery -- Technology application, Immunotherapy -- Technology application, Bacterial infections -- Technology application, Virus diseases -- Technology application, Technology application, General interest, News, opinion and commentary
Abstract

LONDON: Frost & Sullivan has issued the following news release: Based on its recent analysis of the European AI-enabled drug discovery market, Frost & Sullivan recognizes Evaxion Biotech A/S (Evaxion) [...]

Published
2021

75. Avalon GloboCare Jointly Files US and International Patent Application for Breakthrough S-Layer Coated Emulsome Technology (SLET) for Next-Generation Drug Delivery and Cellular Immunotherapy

Subjects
Drugs -- Vehicles, Immunotherapy -- Technology application, Drug delivery systems -- Technology application -- Intellectual property, Technology application, Banking, finance and accounting industries, Business
Abstract

FREEHOLD, N.J., Oct 14, 2021 (GLOBE NEWSWIRE via COMTEX) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced [...]

Published
2021

76. United States : Evaxion Biotech Lauded by Frost & Sullivan for Helping Develop Highly Targeted Therapies with Its AI Immunology Platforms

Subjects
Biotechnology -- Technology application, Drug discovery -- Technology application, Immunotherapy -- Technology application, Bacterial infections -- Technology application, Virus diseases -- Technology application, Technology application, Business, international
Abstract

Based on its recent analysis of the European AI-enabled drug discovery market, Frost & Sullivan recognizes Evaxion Biotech A/S (Evaxion) with the 2021 Europe Enabling Technology Leadership Award for aiding [...]

Published
2021

77. Australian biotech, EnGeneIC, develops world-first nanocellular anti-COVID-19 vaccine that defeats mutant viruses and stimulates a broad anti-viral response

Subjects
Biotechnology -- Technology application, Immunotherapy -- Technology application, Vaccines -- Technology application, Technology application, General interest, News, opinion and commentary
Abstract

SYDNEY: EnGeneIC has issued the following news release: EnGeneIC Limited, an Australian, Sydney-based biotechnology company, has developed a globally unique nanocellular technology that in pre-clinical animal studies has been shown [...]

Published
2021

78. Australian biotech, EnGeneIC, develops world-first nanocellular anti-COVID-19 vaccine that defeats mutant viruses and stimulates a broad anti-viral response

Subjects
Biotechnology -- Technology application, Immunotherapy -- Technology application, Vaccines -- Technology application, Technology application, Business, international, Law
Abstract

(GlobeNewswire) - EnGeneIC Limited, an Australian, Sydney-based biotechnology company, has developed a globally unique nanocellular technology that in pre-clinical animal studies has been shown to stimulate a broad and powerful [...]

Published
2021

79. Australian biotech, EnGeneIC, develops world-first nanocellular anti-COVID-19 vaccine that defeats mutant viruses and stimulates a broad anti-viral response

Subjects
Biotechnology -- Technology application, Immunotherapy -- Technology application, Vaccines -- Technology application, Technology application, Banking, finance and accounting industries, Business
Abstract

SYDNEY and NEW YORK, Sep 07, 2021 (GLOBE NEWSWIRE via COMTEX) -- -- Works against mutant strains including Delta EnGeneIC Limited, an Australian, Sydney-based biotechnology company, has developed a globally [...]

Published
2021

80. Fight against COVID-19: Evonik supplies key technology for gene-based drugs

Subjects
Vaccines -- Technology application, Drug delivery systems -- Technology application, Genes -- Technology application, Immunotherapy -- Technology application, COVID-19 -- Technology application, RNA -- Technology application, Technology application, News, opinion and commentary
Abstract

The COVID-19 pandemic has prompted a breakthrough in gene-based vaccines using a technology in which Evonik is a global leader. Currently, the only established process for transporting mRNA vaccines into [...]

Published
2020

82. Celsion Corporation reports Q2 2021 financial results and provides business update

Subjects
Celsion Corp. -- Company sales and earnings, Medical test kit industry -- Company sales and earnings, Immunotherapy -- Technology application, Medical equipment and supplies industry -- Company sales and earnings, Vaccines -- Technology application, Ovarian cancer -- Technology application, Technology application, Company earnings/profit, General interest, News, opinion and commentary
Abstract

LAWRENCEVILLE, N.J.: Celsion Corporation, a clinical-stage drug-development company focused on DNA-based immunotherapy and next-generation vaccines, announced financial results for the three and six months ended June 30, 2021, and provided [...]

Published
2021

83. ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific Antibody

Subjects
Viral antibodies -- Technology application, Immunotherapy -- Technology application, Antibodies -- Technology application, Technology application, Business, News, opinion and commentary
Abstract

ABL503/TJ-L14B demonstrates stronger anti-tumor efficacy than anti-PD-L1 or anti-4-1BB monotherapy as well as a good safety profile ABL503 currently in Phase 1 trial to evaluate the safety, tolerability, MTD PK [...]

Published
2021

84. Intrommune Therapeutics to Present at BIO Digital 2021

Subjects
Biotechnology industry -- Technology application, Immunotherapy -- Technology application, Food allergy -- Technology application, Technology application, Telecommunications industry
Abstract

(GlobeNewswire) - Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced today that it will be presenting at [...]

Published
2021

85. Intrommune Therapeutics to Present at BIO Digital 2021

Subjects
Biotechnology industry -- Technology application, Immunotherapy -- Technology application, Food allergy -- Technology application, Technology application, Business, international, Law
Abstract

(GlobeNewswire) - Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced today that it will be presenting at [...]

Published
2021

86. Intrommune Therapeutics to Present at BIO Digital 2021

Subjects
Biotechnology industry -- Technology application, Immunotherapy -- Technology application, Food allergy -- Technology application, Technology application, Banking, finance and accounting industries, Business
Abstract

NEW YORK, June 17, Jun 17, 2021 (GLOBE NEWSWIRE via COMTEX) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other [...]

Published
2021

87. XcellBio, Carolina BioOncology Institute collaborate to advance immunotherapeutic development

Subjects
Precision medicine -- Technology application, Immunotherapy -- Technology application, Control systems -- Technology application, Technology application, Pharmaceuticals and cosmetics industries
Abstract

XcellBio, a proprietary provider of primary cell control technologies for immunotherapeutic solutions, has announced a collaboration with Carolina BioOncology Institute (CBI) to further pre-clinical development of true personalized medicine therapies. [...]

Published
2018

88. GE Healthcare to provide semi-automated end-to-end manufacturing platform, FlexFactory to Xiangxue Pharmaceutical

Subjects
Immunotherapy -- Technology application, T cells -- Technology application, Technology application, Pharmaceuticals and cosmetics industries
Abstract

GE Healthcare will provide Xiangxue Pharmaceutical Co., Ltd. (XPH) with a FlexFactory for cell therapy, a semi-automated end-to-end manufacturing platform, to help scale up, digitize and accelerate manufacturing processes for [...]

Published
2018

89. Celsion Corporation to Hold Year-End 2020 Financial Results and Business Update Conference Call on Friday, March 19, 2021

Subjects
Celsion Corp. -- Technology application, Medical test kit industry -- Technology application, Immunotherapy -- Technology application, Medical equipment and supplies industry -- Technology application, Vaccines -- Technology application, Ovarian cancer -- Technology application, Technology application, General interest, News, opinion and commentary
Abstract

Lawrenceville: Celsion Corporation.has issued the following press release: Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host [...]

Published
2021

90. Celsion Corporation to Hold Year-End 2020 Financial Results and Business Update Conference Call on Friday, March 19, 2021

Subjects
Celsion Corp. -- Technology application, Medical test kit industry -- Technology application, Immunotherapy -- Technology application, Medical equipment and supplies industry -- Technology application, Vaccines -- Technology application, Ovarian cancer -- Technology application, Technology application, Banking, finance and accounting industries, Business
Abstract

LAWRENCEVILLE, Mar 12, 2021 (GLOBE NEWSWIRE via COMTEX) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will [...]

Published
2021

91. Molecular Partners Nominates Agnete Fredriksen for Election to Its Board of Directors

Subjects
Immunotherapy -- Technology application, Technology application, General interest, News, opinion and commentary
Abstract

ZURICH-SCHLIEREN: Molecular Partners AG has issued the following news release: Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as [...]

Published
2021

92. OncoSec Strengthens IP Portfolio with Allowance of Two European Patent Applications Covering TAVO and Its Gene Electrotransfer Technology

Subjects
Genes -- Technology application, Immunotherapy -- Technology application, Pembrolizumab -- Technology application, Technology application, General interest, News, opinion and commentary
Abstract

California: OncoSec Medical Incorporated has issued the following press release: OncoSec Medical Incorporated (NASDAQ:ONCS) (the 'Company' or 'OncoSec') today announced that the European Patent Office has issued notices of intention [...]

Published
2020

93. OncoSec Strengthens IP Portfolio with Allowance of Two European Patent Applications Covering TAVO(TM) and Its Gene Electrotransfer Technology

Subjects
Genes -- Technology application, Immunotherapy -- Technology application, Cancer -- Care and treatment, Interleukins -- Intellectual property -- Technology application, Technology application, Business, News, opinion and commentary
Abstract

-- Allowed claims cover methods to deliver TAVO using intratumoral gene electrotransfer in combination with a PD-1/PD-L1 inhibitor PENNINGTON, N.J. and SAN DIEGO, Dec. 10, 2020 /PRNewswire/ -- OncoSec Medical [...]

Published
2020

94. Fight against COVID-19: Evonik supplies key technology for gene-based drugs

Subjects
Evonik Industries AG -- Technology application, Vaccines -- Technology application, Specialty chemicals industry -- Technology application, Genes -- Technology application, Immunotherapy -- Technology application, COVID-19 -- Technology application, RNA -- Technology application, Technology application, General interest, News, opinion and commentary
Abstract

Essen, Germany: Evonik Industries AG has issued the following press release: The COVID-19 pandemic has prompted a breakthrough in gene-based vaccines using a technology in which Evonik is a global [...]

Published
2020

95. Germany : Fight against COVID-19: Evonik supplies key technology for gene-based drugs

Subjects
Vaccines -- Technology application, Genes -- Technology application, Immunotherapy -- Technology application, COVID-19 -- Technology application, RNA -- Technology application, Technology application, Business, international
Abstract

The COVID-19 pandemic has prompted a breakthrough in gene-based vaccines using a technology in which Evonik is a global leader. Currently, the only established process for transporting mRNA vaccines into [...]

Published
2020

96. Applied Cells Announces New MARS(r) Bar System

Subjects
Immunotherapy -- Technology application, Technology application, General interest, News, opinion and commentary
Abstract

SANTA CLARA: Applied Cells Inc. has issued the following press release: Applied Cells, Inc., announced today that the company will unveil its MARS(r) Bar System, a revolutionary fully automated high-capacity [...]

Published
2020

97. Applied Cells Announces New MARS Bar System

Subjects
Immunotherapy -- Technology application, Technology application, Business, News, opinion and commentary
Abstract

SANTA CLARA, Calif., Dec. 2, 2020 /PRNewswire/ -- Applied Cells, Inc., announced today that the company will unveil its MARS Bar System, a revolutionary fully automated high-capacity closed system for [...]

Published
2020

98. Evaxion Biotech Lauded by Frost & Sullivan for Helping Develop Highly Targeted Therapies with Its AI Immunology Platforms

Subjects
Biotechnology -- Technology application, Drug discovery -- Technology application, Immunotherapy -- Technology application, Bacterial infections -- Technology application, Vaccines -- Technology application, Virus diseases -- Technology application, Technology application, Health
Abstract

2021 OCT 27 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- Based on its recent analysis of the European AI-enabled drug discovery market, Frost & Sullivan [...]

Published
2021

99. Panel Discussion on COVID-19: How Has the RNA Industry Adapted to Beat the Pandemic

Subjects
Pfizer Inc. -- Technology application, Vaccines -- Technology application, Immunotherapy -- Technology application, Pharmaceutical industry -- Technology application, COVID-19 -- Care and treatment, RNA -- Technology application, Technology application, Business
Abstract

London, United Kingdom, November 15, 2020 --(PR.com)-- RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy personalised medicines, and treatment of genetic, infectious and chronic diseases. [...]

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results